In Vitro Diagnostics Global market - Forecast to 2028

Publishing Date : September, 2021
Report Code : HCMD 0099
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

In-vitro diagnostic (IVD) are tests where reagents, instruments, and systems determine the state of health, to cure, mitigate, treat, or prevent disease. These tests can be performed on a variety of instruments such as small, handheld tests to complex laboratory instruments allowing doctors to diagnose patients effectively and decide to provide appropriate treatments.

According to IQ4I analysis, the In vitro diagnostic global market is expected to grow at low single digit CAGR from 2021 to 2028 to reach $96,485.2 million by 2028. The factors such as the growing incidence of chronic and infectious diseases, increasing adoption of point-of-care testing, the emergence of Next-generation molecular diagnostics, minimally invasive and non-invasive in-vitro diagnostics, rising number of CLIA-waived tests are driving the growth of the IVD market. However, the rising number of product recalls, lack of skilled laboratory technicians in developing nations, inadequate reimbursements, and stringent regulatory framework is expected to hamper the market growth.

The in-vitro diagnostics global market is segmented based on products, technology, applications, sample source, end-users and geography. The products market is segmented into instruments, reagents and software & services, where, reagents commanded the largest share of the market in 2021 and is expected to grow at low single digit CAGR from 2021 to 2028.

The IVD global market based on technology is segmented into immunochemistry, clinical chemistry, molecular diagnostics, clinical microbiology, hematology, coagulation and hemostasis and others. Among these, the immunochemistry segment commanded the largest share in 2021 and the market is expected to grow at low single digit CAGR from 2021 to 2028. The immunochemistry market is further sub-segmented based on techniques into Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot (Elispot) Assay, Radioimmunoassay (RIA), Rapid Tests, Chemiluminescence Immunoassay (CLIA), Fluoro Immunoassay (FIA), and Others. Among these, ELISA commanded the largest share in 2021; the rapid test segment occupied a significant share of the techniques market in 2021. The clinical chemistry market is sub-segmented based on technique into basic metabolic profile, electrolyte panel, liver panel, lipid profile, renal profile, thyroid function panel and others, among which, the basic metabolic profile commanded the largest share of the market in 2021, the lipid profile segment is expected to grow at a high single digit CAGR from 2021 to 2028. The molecular diagnostics market is further sub-segmented into PCR, microfluidics & microarray, INAAT, in-situ hybridization, NGS and others. Among these, the PCR segment generated the largest revenue in 2021, Microfluidics & microarray segment is expected to grow at early teen CAGR from 2021 to 2028.

The IVD global market based on application is segmented into oncology, diabetes, infectious diseases, genetic testing, cardiology, autoimmune diseases, drug testing, nephrology, transplantation, Blood & related disorders, and others, among them, the infectious disease segment commanded the largest revenue in 2021, the transplantation segment is expected to grow at high double digit CAGR from 2021 to 2028. The oncology market is further sub-segmented based on cancer types into lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer and others, among which, colorectal cancer commanded the largest share in 2021 and the market is expected to grow at a high single digit CAGR from 2021 to 2028. The oncology market based on cancer care is further sub-segmented into diagnosis, early screening, companion diagnostics, prognosis and recurrence monitoring, where, diagnosis commanded the largest share of the market in 2021, the companion diagnostics segment is expected to grow at high single digit CAGR from 2021 to 2028. The infectious disease market is further sub-segment into bacterial, viral infection, fungal and others among which the viral infection commanded the largest share of the market in 2021. The bacterial infection global market is further segmented based on infection agent into Treponema pallidum, Gardnerella, Staphylococcus aureus, Clostridium difficile, Streptococcus (A&B), Methicillin-resistant Staphylococcus aureus (MRSA), Chlamydia trachomatis (CT) & Neisseria gonorrhea (NG) and tuberculosis (TB) and others. Among these, Staphylococcus aureus commanded the largest revenue in 2021. The MRSA segment is expected to grow at low single digit CAGR from 2021 to 2028. The Viral infection global market is segmented based on the type of infection into HIV-1, influenza, dengue, Hepatitis B, Hepatitis C, Human papillomavirus (HPV), herpes simplex virus (HSC), zika virus, and COVID & others. Among these, the COVID & others segment contributed the largest share of the market in 2021, HIV-1 segment is expected to grow at a double digit CAGR from 2021 to 2028. The Fungal infection global market based on the type of infection is segmented into Candida, Aspergillus, and others. Among these, Candida commanded the largest revenue in 2021. The other infections segment is further sub-segmented into malaria, trichomonas vaginalis and others, among this, Trichomonas vaginalis commanded the largest share in 2021, and malaria is expected to grow at low single digit CAGR from 2021 to 2028.

The IVD global market based on sample source is segmented into blood, urine, mucus and others, among which blood commanded the largest share of the market in 2021, and is expected to grow at mid single digit CAGR from 2021 to 2028. The blood-based tests provide accurate results when compare to other sources, and, they are suitable sample sources for early diagnosis before the occurrence of symptoms.

The In-vitro diagnostics end-user market is segmented into diagnostic laboratories, hospitals, academics and research centers, homecare and other end-users. The hospitals' segment accounted for the largest revenue in 2021 and is estimated to grow at low single digit CAGR from 2021 to 2028 due to the availability of advanced and novel technologies for the diagnosis and also the availability of skilled professionals with more capital investments.

Geographical-wise, the North America region commanded the largest revenue in 2021 owing to the high demand for early detection, treatment and prevention tests with advanced technology. However, the Asia-Pacific region is expected to grow at mid single digit CAGR from 2021 to 2028 with increasing awareness for the highly precise, rapid and advanced tests for a better outcome.

The in-vitro diagnostics global market is competitive and all the active players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the IVD global market include Abbott Laboratories, Inc. (U.S.), F.Hoffmann-La Roche AG (Switzerland), Siemens Healthineers(Germany), Biomerieux SA (France), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Sysmex (Japan), Dexcom (U.S), Hologic (U.S), Quidel (U.S) Qiagen N.V. (the Netherlands) and Thermo Fisher Scientific, Inc. (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World (RoW)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN & DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     GROWING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES
        • 3.3.1.2     INCREASE IN DEMAND FOR IVD TESTS DUE TO COVID-19 PANDEMIC
        • 3.3.1.3     INCREASING ADOPTION OF POINT-OF-CARE TESTING
        • 3.3.1.4     THE EMERGENCE OF NEXT-GENERATION MOLECULAR DIAGNOSTICS
        • 3.3.1.5     GROWING AWARENESS OF COMPANION DIAGNOSTICS AND PERSONALIZED MEDICINE
        • 3.3.1.6     THE EMERGENCE OF MINIMALLY INVASIVE AND NON-INVASIVE DIAGNOSTICS
        • 3.3.1.7     RISING NUMBER OF CLIA-WAIVED IVD TESTS
      • 3.3.2     RESTRAINTS & THREATS
        • 3.3.2.1     RISING INCIDENCE OF PRODUCT RECALLS
        • 3.3.2.2     LACK OF SKILLED LABORATORY TECHNICIANS IN DEVELOPING NATIONS
        • 3.3.2.3     INADEQUATE REIMBURSEMENT
        • 3.3.2.4     STRINGENT REGULATORY FRAMEWORK
    • 3.4     PORTER’S FIVE FORCE ANALYSIS
      • 3.4.1     THREAT OF NEW ENTRANTS
      • 3.4.2     THREAT OF SUBSTITUTES
      • 3.4.3     COMPETITIVE RIVALRY
      • 3.4.4     BARGAINING POWER OF SUPPLIERS
      • 3.4.5     BARGAINING POWER OF BUYERS
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.A
      • 3.5.2     EUROPE
      • 3.5.3     CHINA
      • 3.5.4     INDIA
      • 3.5.5     JAPAN
      • 3.5.6     AUSTRALIA
      • 3.5.7     SOUTH KOREA
    • 3.6     TECHNOLOGICAL ADVANCEMENTS
    • 3.7     FUNDING SCENARIO
    • 3.8     MERGERS & ACQUISITIONS
    • 3.9     SUPPLY CHAIN ANALYSIS
    • 3.10     IMPACT OF COVID-19
    • 3.11     CLINICAL TRIALS
      • 3.11.1     CFDNA CLINICALTRIALS
      • 3.11.2     CIRCULATING TUMOR CELLS (CTC)
      • 3.11.3     COMPANION DIAGNOSTICS
      • 3.11.4     IMMUNOASSAYS
      • 3.11.5     LIPID PROFILE
      • 3.11.6     MICROARRAY
      • 3.11.7     GENETIC DISEASES
    • 3.12     MARKET SHARE ANALYSIS BY IN-VITRO DIAGNOSTICS MAJOR PLAYERS
      • 3.12.1     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
      • 3.12.2     IMMUNOCHEMISTRY GLOBAL MARKET SHARE ANALYSIS
      • 3.12.3     CLINICAL CHEMISTRY GLOBAL MARKET SHARE ANALYSIS
      • 3.12.4     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS
      • 3.12.5     CLINICAL MICROBIOLOGY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.12.6     HEMATOLOGY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.12.7     COAGULATION AND HEMOSTASIS MARKET SHARE ANALYSIS BY MAJOR PLAYERS
  • 4     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     INSTRUMENTS
    • 4.3     REAGENTS
    • 4.4     SOFTWARE AND SERVICES
  • 5     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY
    • 5.1     INTRODUCTION
    • 5.2     IMMUNOCHEMISTRY
      • 5.2.1     ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
      • 5.2.2     ENZYME-LINKED IMMUNOSPOT (ELISPOT) ASSAY
      • 5.2.3     RADIOIMMUNOASSAY (RIA)
      • 5.2.4     RAPID TESTS
      • 5.2.5     CHEMILUMINESCENCE IMMUNOASSAYS (CLIA)
      • 5.2.6     FLUORESCENCE IMMUNOASSAYS (FIA)
      • 5.2.7     OTHER IMMUNOASSAYS
    • 5.3     CLINICAL CHEMISTRY
      • 5.3.1     BASIC METABOLIC PROFILE
      • 5.3.2     ELECTROLYTE PANEL
      • 5.3.3     LIVER PANEL
      • 5.3.4     LIPID PANEL
      • 5.3.5     RENAL PANEL
      • 5.3.6     THYROID FUNCTION PANEL
      • 5.3.7     OTHERS (CLINICAL CHEMISTRY TESTS)
    • 5.4     MOLECULAR DIAGNOSTICS (MDX)
      • 5.4.1     PCR (POLYMERASE CHAIN REACTION)
      • 5.4.2     ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
      • 5.4.3     MICROFLUIDICS & MICROARRAY
      • 5.4.4     IN SITU HYBRIDIZATION (ISH)
      • 5.4.5     NEXT-GENERATION SEQUENCING (NGS)
      • 5.4.6     OTHER MDX TECHNOLOGIES
    • 5.5     CLINICAL MICROBIOLOGY
    • 5.6     HEMATOLOGY
    • 5.7     COAGULATION AND HEMOSTASIS
    • 5.8     OTHERS
  • 6     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     ONCOLOGY
      • 6.2.1     CANCER TYPES
        • 6.2.1.1     INTRODUCTION
        • 6.2.1.2     LUNG CANCER
        • 6.2.1.3     BREAST CANCER
        • 6.2.1.4     COLORECTAL CANCER
        • 6.2.1.5     PROSTATE CANCER
        • 6.2.1.6     MELANOMA
        • 6.2.1.7     OVARIAN CANCER
        • 6.2.1.8     OTHERS
      • 6.2.2     CANCER CARE
        • 6.2.2.1     INTRODUCTION
        • 6.2.2.2     DIAGNOSIS
        • 6.2.2.3     EARLY SCREENING
        • 6.2.2.4     COMPANION DIAGNOSTICS
        • 6.2.2.5     PROGNOSIS MONITORING
        • 6.2.2.6     RECURRENCE MONITORING
    • 6.3     DIABETES
    • 6.4     INFECTIOUS DISEASES
      • 6.4.1     BACTERIAL INFECTION
        • 6.4.1.1     TREPONEMA PALLIDUM
        • 6.4.1.2     GARDNERELLA VAGINALIS
        • 6.4.1.3     STAPHYLOCOCCUS AUREUS
        • 6.4.1.4     CLOSTRIDIUM DIFFICILE
        • 6.4.1.5     STREPTOCOCCUS (A & B)
        • 6.4.1.6     METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
        • 6.4.1.7     CHLAMYDIA TRACHOMATIS (CT) AND NEISSERIA GONORRHOEAE (NG)
        • 6.4.1.8     TUBERCULOSIS (TB)
        • 6.4.1.9     OTHER BACTERIAL INFECTION
      • 6.4.2     VIRAL INFECTION
        • 6.4.2.1     HIV-1
        • 6.4.2.2     INFLUENZA
        • 6.4.2.3     DENGUE
        • 6.4.2.4     HEPATITIS B
        • 6.4.2.5     HEPATITIS C
        • 6.4.2.6     HUMAN PAPILLOMA VIRUS (HPV)
        • 6.4.2.7     HERPES SIMPLEX VIRUS (HSV)
        • 6.4.2.8     ZIKA VIRUS
        • 6.4.2.9     COVID AND OTHER VIRAL INFECTION
      • 6.4.3     FUNGAL INFECTION
        • 6.4.3.1     CANDIDA
        • 6.4.3.2     ASPERGILLUS
        • 6.4.3.3     OTHER FUNGAL INFECTION
      • 6.4.4     OTHER INFECTION
        • 6.4.4.1     MALARIA
        • 6.4.4.2     TRICHOMONAS VAGINALIS
        • 6.4.4.3     OTHER INFECTIONS
    • 6.5     GENETIC TESTING
    • 6.6     CARDIOLOGY DISEASES
    • 6.7     AUTOIMMUNE DISEASES
    • 6.8     DRUG TESTING
    • 6.9     NEPHROLOGY
    • 6.10     TRANSPLANTATION
    • 6.11     BLOOD AND RELATED DISORDERS
    • 6.12     OTHER DISEASES
  • 7     IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE
    • 7.1     INTRODUCTION
    • 7.2     BLOOD
    • 7.3     MUCUS
    • 7.4     URINE
    • 7.5     OTHERS
  • 8     IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY END-USER
    • 8.1     INTRODUCTION
    • 8.2     DIAGNOSTIC LABORATORIES
    • 8.3     HOSPITALS
    • 8.4     ACADEMIC & RESEARCH CENTRES
    • 8.5     HOME CARE
    • 8.6     OTHER END-USERS
  • 9     REGIONAL MARKET ANALYSIS
    • 9.1     INTRODUCTION
    • 9.2     NORTH AMERICA
      • 9.2.1     U.S.
      • 9.2.2     REST OF NORTH AMERICA
    • 9.3     EUROPE
      • 9.3.1     GERMANY
      • 9.3.2     U.K.
      • 9.3.3     FRANCE
      • 9.3.4     REST OF E.U.
    • 9.4     ASIA PACIFIC
      • 9.4.1     JAPAN
      • 9.4.2     CHINA
      • 9.4.3     INDIA
      • 9.4.4     REST OF APAC
    • 9.5     REST OF THE WORLD
      • 9.5.1     BRAZIL
      • 9.5.2     REST OF LATIN AMERICA
      • 9.5.3     MIDDLE EAST AND OTHERS
  • 10     COMPANY DEVELOPMENTS
    • 10.1     INTRODUCTION
      • 10.1.1     REGULATORY APPROVAL AS A MAJOR GROWTH STRATEGY OF IN-VITRO DIAGNOSTICS MARKET PLAYERS
    • 10.2     APPROVAL
    • 10.3     NEW PRODUCT LAUNCH
    • 10.4     AGREEMENTS PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
    • 10.5     MERGERS AND ACQUISITIONS
    • 10.6     BUSINESS EXPANSION
  • 11     COMPANY PROFILES
    • 11.1     ABBOTT LABORATORIES
      • 11.1.1     OVERVIEW
      • 11.1.2     FINANCIALS
      • 11.1.3     PRODUCT PORTFOLIO
      • 11.1.4     KEY DEVELOPMENTS
      • 11.1.5     BUSINESS STRATEGY
      • 11.1.6     SWOT ANALYSIS
    • 11.2     BIOMERIEUX
      • 11.2.1     OVERVIEW
      • 11.2.2     FINANCIALS
      • 11.2.3     PRODUCT PORTFOLIO
      • 11.2.4     KEY DEVELOPMENTS
      • 11.2.5     BUSINESS STRATEGY
      • 11.2.6     SWOT ANALYSIS
    • 11.3     DANAHER CORPORATION
      • 11.3.1     OVERVIEW
      • 11.3.2     FINANCIALS
      • 11.3.3     PRODUCT PORTFOLIO
      • 11.3.4     KEY DEVELOPMENTS
      • 11.3.5     BUSINESS STRATEGY
      • 11.3.6     SWOT ANALYSIS
    • 11.4     DEXCOM, INC.
      • 11.4.1     OVERVIEW
      • 11.4.2     FINANCIALS
      • 11.4.3     PRODUCT PORTFOLIO
      • 11.4.4     KEY DEVELOPMENTS
      • 11.4.5     BUSINESS STRATEGY
      • 11.4.6     SWOT ANALYSIS
    • 11.5     F. HOFFMANN LA ROCHE
      • 11.5.1     OVERVIEW
      • 11.5.2     FINANCIALS
      • 11.5.3     PRODUCT PORTFOLIO
      • 11.5.4     KEY DEVELOPMENTS
      • 11.5.5     BUSINESS STRATEGY
      • 11.5.6     SWOT ANALYSIS
    • 11.6     HOLOGIC, INC.
      • 11.6.1     OVERVIEW
      • 11.6.2     FINANCIALS
      • 11.6.3     PRODUCT PORTFOLIO
      • 11.6.4     KEY DEVELOPMENTS
      • 11.6.5     BUSINESS STRATEGY
      • 11.6.6     SWOT ANALYSIS
    • 11.7     QUIDEL CORPORATION
      • 11.7.1     OVERVIEW
      • 11.7.2     FINANCIALS
      • 11.7.3     PRODUCT PORTFOLIO
      • 11.7.4     KEY DEVELOPMENTS
      • 11.7.5     BUSINESS STRATEGY
      • 11.7.6     SWOT ANALYSIS
    • 11.8      SIEMENS HEALTHINEERS
      • 11.8.1     OVERVIEW
      • 11.8.2     FINANCIALS
      • 11.8.3     PRODUCT PORTFOLIO
      • 11.8.4     KEY DEVELOPMENTS
      • 11.8.5     BUSINESS STRATEGY
      • 11.8.6     SWOT ANALYSIS
    • 11.9     SYSMEX
      • 11.9.1     OVERVIEW
      • 11.9.2     FINANCIALS
      • 11.9.3     PRODUCT PORTFOLIO
      • 11.9.4     KEY DEVELOPMENTS
      • 11.9.5     BUSINESS STRATEGY
      • 11.9.6     SWOT ANALYSIS
    • 11.10     THERMO FISHER SCIENTIFIC
      • 11.10.1     OVERVIEW
      • 11.10.2     FINANCIALS
      • 11.10.3     PRODUCT PORTFOLIO
      • 11.10.4     KEY DEVELOPMENTS
      • 11.10.5     BUSINESS STRATEGY
      • 11.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 2     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCT (2020-2028) ($MN)
      • TABLE 3     IN-VITRO DIAGNOSTICS INSTRUMENTS GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 4     IN-VITRO DIAGNOSTICS REAGENTS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 5     IN-VITRO DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 6     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2020-2028) ($MN)
      • TABLE 7     IMMUNOCHEMISTRY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 8     IMMUNOCHEMISTRY GLOBAL MARKET REVENUE, BY TECHNIQUE (2020-2028) ($MN)
      • TABLE 9     ELISA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 10     ELISPOT GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 11     RADIOIMMUNOASSAY (RIA) GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 12     RAPID TESTS GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 13     CHEMILUMINESCENCE IMMUNOASSAYS (CLIA) GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 14     FLUORESCENCE IMMUNOASSAYS (FIA) GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 15     OTHER IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 16     CLINICAL CHEMISTRY GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 17     CLINICAL CHEMISTRY GLOBAL MARKET REVENUE, BY TECHNIQUE (2020-2028) ($MN)
      • TABLE 18     BASIC METABOLIC PROFILE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 19     ELECTROLYTE PANEL GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 20     LIVER PANEL GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 21     LIPID PANEL GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 22     RENAL PROFILE GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 23     THYROID FUNCTION PANEL GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 24     OTHER GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • TABLE 25     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 26     MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNIQUE (2020-2028) ($MN)
      • TABLE 27     PCR GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 28     INAAT GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 29     MICROFLUIDICS & MICROARRAY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 30     IN SITU HYBRIDIZATION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 31     NGS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 32     OTHER MDX TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 33     CLINICAL MICROBIOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 34     HEMATOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 35     COAGULATION AND HEMOSTASIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 36     OTHER TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 37     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION (2020-2028) ($MN)
      • TABLE 38     ONCOLOGY GLOBAL MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
      • TABLE 39     ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 40     LUNG CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 41     BREAST CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 42     COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 43     PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 44     MELANOMA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 45     OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 46     OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 47     CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
      • TABLE 48     DIAGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 49     EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 50     COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 51     PROGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 52     RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 53     DIABETES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 54     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
      • TABLE 55     INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 56     BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY INFECTION (2020-2028) ($MN)
      • TABLE 57     BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 58     TREPONEMA PALLIDUM GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 59     GARDNERELLA VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 60     S. AUREUS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 61     CLOSTRIDIUM DIFFICILE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 62     STREPTOCOCCUS (A & B) GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 63     MRSA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 64     CT/NG GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 65     TUBERCULOSIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 66     OTHER BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 67     VIRAL INFECTION GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2020-2028) ($MN)
      • TABLE 68     VIRAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 69     HIV-1 GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 70     INFLUENZA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 71     DENGUE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 72     HEPATITIS B GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 73     HEPATITIS C GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 74     HPV GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 75     HSV GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 76     ZIKA VIRUS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 77     COVID AND OTHER VIRUSES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 78     FUNGAL INFECTION GLOBAL MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 79     FUNGAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 80     CANDIDA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 81     ASPERGILLUS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 82     OTHER FUNGAL GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 83     OTHER INFECTIONS GLOBAL MARKET REVENUE, BY TYPE, (2020-2028) ($MN)
      • TABLE 84     MALARIA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 85     TRICHOMONAS VAGINALIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 86     OTHER INFECTIONS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 87     GENETIC TESTING GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 88     CARDIOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 89     AUTOIMMUNE DISEASES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 90     DRUG TESTING GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 91     NEPHROLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 92     TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 93     BLOOD AND RELATED DISORDER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 94     OTHER DISEASES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 95     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
      • TABLE 96     BLOOD SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 97     MUCUS SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 98     URINE SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 99     OTHER SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 100     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2020-2028) ($MN)
      • TABLE 101     DIAGNOSTIC LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 102     HOSPITALS END-USER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 103     ACADEMICS AND RESEARCH CENTERS END-USER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 104     HOME CARE END-USERS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 105     OTHER END USERS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 106     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN)
      • TABLE 107     NORTH AMERICA IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN)
      • TABLE 108     NORTH AMERICA IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN)
      • TABLE 109     NORTH AMERICA IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 110     NORTH AMERICA CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 111     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 112     NORTH AMERICA IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
      • TABLE 113     NORTH AMERICA ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
      • TABLE 114     NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
      • TABLE 115     NORTH AMERICA INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
      • TABLE 116     NORTH AMERICA BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 117     NORTH AMERICA VIRAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 118     NORTH AMERICA FUNGAL INFECTION MARKET REVENUE, BY INFECTION, (2020-2028) ($MN)
      • TABLE 119     NORTH AMERICA OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 120     NORTH AMERICA IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
      • TABLE 121     NORTH AMERICA IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN)
      • TABLE 122     NORTH AMERICA IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN)
      • TABLE 123     EUROPE IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN)
      • TABLE 124     EUROPE IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN)
      • TABLE 125     EUROPE IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 126     EUROPE CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 127     EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 128     EUROPE IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
      • TABLE 129     EUROPE ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
      • TABLE 130     EUROPE ONCOLOGY MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
      • TABLE 131     EUROPE INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
      • TABLE 132     EUROPE BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 133     EUROPE VIRAL INFECTION MARKET REVENUE, BY INFECTION, (2020-2028) ($MN)
      • TABLE 134     EUROPE FUNGAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 135     EUROPE OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 136     EUROPE IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
      • TABLE 137     EUROPE IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN)
      • TABLE 138     EUROPE IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN)
      • TABLE 139     APAC IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN)
      • TABLE 140     APAC IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN)
      • TABLE 141     APAC IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 142     APAC CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 143     APAC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 144     APAC IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
      • TABLE 145     APAC ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
      • TABLE 146     APAC ONCOLOGY MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
      • TABLE 147     APAC INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
      • TABLE 148     APAC BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 149     APAC VIRAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 150     APAC FUNGAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 151     APAC OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 152     APAC IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
      • TABLE 153     APAC IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN)
      • TABLE 154     APAC IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN)
      • TABLE 155     ROW IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN)
      • TABLE 156     ROW IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN)
      • TABLE 157     ROW IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 158     ROW CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 159     ROW MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN)
      • TABLE 160     ROW IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
      • TABLE 161     ROW ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN)
      • TABLE 162     ROW CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN)
      • TABLE 163     ROW INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN)
      • TABLE 164     ROW BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 165     ROW VIRAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 166     ROW FUNGAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 167     ROW OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN)
      • TABLE 168     ROW IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN)
      • TABLE 169     ROW IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN)
      • TABLE 170     ROW IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN)
      • TABLE 171     APPROVALS (2020-2021)
      • TABLE 172     NEW PRODUCT LAUNCH (2020-2021)
      • TABLE 173     COLLABORATIONS (2020-2021)
      • TABLE 174     MERGERS AND ACQUISITIONS (2020-2021)
      • TABLE 175     BUSINESS EXPANSION (2020-2021)
      • TABLE 176     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
      • TABLE 177     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 178     ABBOTT LABORATORIES: DIAGNOSTICS, BY SUB-SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 179     ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
      • TABLE 180     BIOMERIEUX: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
      • TABLE 181     BIOMERIEUX: TOTAL REVENUE, BY SEGMENTS, (2019-2021)(Q2) ($MN)
      • TABLE 182     BIOMERIEUX: TOTAL REVENUE, BY SUB SEGMENTS, (2019-2021)(Q2) ($MN)
      • TABLE 183     BIOMERIEUX: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
      • TABLE 184     DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
      • TABLE 185     DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 186     DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
      • TABLE 187     DEXCOM, INC: TOTAL REVENUE AND R&D EXPENSES (2019-2021) (Q2) ($MN)
      • TABLE 188     DEXCOM, INC: TOTAL REVENUE, BY SEGMENT (2019-2021)(Q2) ($MN)
      • TABLE 189     DEXCOM, INC: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q2) ($MN)
      • TABLE 190     F. HOFFMANN LA ROCHE: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
      • TABLE 191     F. HOFFMANN LA ROCHE: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 192     F. HOFFMANN LA ROCHE: DIAGNOSTICS, BY DIAGNOSTICS SUB-SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 193     HOFFMANN LA ROCHE: DIAGNOSTICS DIVISION TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
      • TABLE 194     HOLOGIC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
      • TABLE 195     HOLOGIC: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 196     HOLOGIC: DIAGNOSTICS, SUB SEGMENTS, (2019-2021) (Q2) ($MN)
      • TABLE 197     HOLOGIC: TOTAL REVENUE, BY GEOGRAPHY, (2020-2021) (Q2) ($MN)
      • TABLE 198     QUIDEL CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
      • TABLE 199     QUIDEL CORPORATION: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 200     QUIDEL CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
      • TABLE 201     SIEMENS HEALTHINEERS: TOTAL REVENUE AND R&D EXPENSES, (2019- 2021) (Q2) ($MN)
      • TABLE 202     SIEMENS HEALTHINEERS: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 203     SIEMENS HEALTHINEERS: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)
      • TABLE 204     SYSMEX: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN)
      • TABLE 205     SYSMEX: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN)
      • TABLE 206     THERMO FISHER SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN)
      • TABLE 207     THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN)
      • TABLE 208     THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN)

      LIST OF FIGURES

      • FIGURE 1     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION (2020-2028) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: IN-VITRO DIAGNOSTICS GLOBAL MARKET
      • FIGURE 3     IN-VITRO DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     IN-VITRO DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     IN-VITRO DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION
      • FIGURE 6     IVD MARKET SEGMENTATION
      • FIGURE 7     IVD TECHNOLOGY MARKET SUB-SEGMENTS
      • FIGURE 8     IVD APPLICATION MARKET SUB-SEGMENTS
      • FIGURE 9     MARKET DYNAMICS
      • FIGURE 10     IN-VITRO DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 11     IN-VITRO DIAGNOSTICS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 12     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021
      • FIGURE 13     IMMUNOCHEMISTRY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021
      • FIGURE 14     CLINICAL CHEMISTRY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021
      • FIGURE 15     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021
      • FIGURE 16     CLINICAL MICROBIOLOGY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021
      • FIGURE 17     HEMATOLOGY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021
      • FIGURE 18     COAGULATION AND HEMOSTASIS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021
      • FIGURE 19     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
      • FIGURE 20     IN-VITRO DIAGNOSTICS INSTRUMENTS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 21     IN-VITRO DIAGNOSTICS REAGENTS MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 22     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY, (2021) (%)
      • FIGURE 23     IMMUNOCHEMISTRY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 24     IMMUNOCHEMISTRY GLOBAL MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 25     ELISA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 26     ELISPOT GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 27     RIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 28     RAPID TESTS GLOBAL MARKET SHARE, BY REGION (2021 V/S 2028) (%)
      • FIGURE 29     CLIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 30     FIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 31     OTHER IMMUNOASSAYS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 32     CLINICAL CHEMISTRY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 33     CLINICAL CHEMISTRY GLOBAL MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 34     BASIC METABOLIC PROFILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 35     ELECTROLYTE PANEL GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 36     LIVER PANEL GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 37     LIPID PANEL GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 38     RENAL PROFILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 39     RENAL PROFILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 40     OTHERS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 41     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 42     MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 43     PCR GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 44     INAAT GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 45     MICROFLUIDICS & MICROARRAY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 46     IN SITU HYBRIDIZATION GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 47     NGS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 48     OTHER MDX TECHNOLOGIES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 49     CLINICAL MICROBIOLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 50     HEMATOLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 51     COAGULATION AND HEMOSTASIS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 52     OTHER TECHNOLOGIES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 53     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 54     ONCOLOGY GLOBAL MARKET SHARE, BY CANCER TYPE, (2021 V/S 2028)(%)
      • FIGURE 55     COLORECTAL CANCER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 56     OTHERS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 57     CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY CANCER CARE, (2021 V/S 2028) (%)
      • FIGURE 58     EARLY SCREENING GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 59     DIABETES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 60     INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 61     INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 62     BACTERIAL INFECTION GLOBAL MARKET SHARE, BY INFECTION, (2021) (%) (CAGR)
      • FIGURE 63     TREPONEMA PALLIDUM GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 64     S. AUREUS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 65     CLOSTRIDIUM DIFFICILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 66     STREPTOCOCCUS (A & B) GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 67     MRSA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 68     CT/NG GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 69     TUBERCULOSIS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 70     OTHER BACTERIAL INFECTION GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 71     VIRAL INFECTIONS GLOBAL MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 72     VIRAL INFECTION GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 73     HIV-1 GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 74     INFLUENZA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 75     DENGUE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 76     HEPATITIS B GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 77     HPV GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 78     HSV GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 79     ZIKA VIRUS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 80     COVID AND OTHER VIRUSES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 81     FUNGAL INFECTION GLOBAL MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 82     OTHER INFECTIONS GLOBAL MARKET SHARE, BY TYPE, (2021 V/S 2028) (%)
      • FIGURE 83     MALARIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 84     TRICHOMONAS VAGINALIS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 85     OTHER INFECTIONS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 86     GENETIC TESTING GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 87     CARDIOLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 88     AUTOIMMUNE DISEASES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 89     DRUG TESTING GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 90     NEPHROLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 91     TRANSPLANTATION GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 92     BLOOD AND RELATED DISORDER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 93     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
      • FIGURE 94     BLOOD SAMPLE SOURCE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 95     URINE SAMPLE SOURCE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 96     OTHER SAMPLE SOURCE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 97     IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
      • FIGURE 98     DIAGNOSTIC LABORATORIES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 99     HOSPITALS END-USER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 100     ACADEMICS AND RESEARCH CENTERS END-USER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 101     HOME CARE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%)
      • FIGURE 102     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN)
      • FIGURE 103     IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION AND COUNTRY, (2021) ($MN)
      • FIGURE 104     NORTH AMERICA IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
      • FIGURE 105     NORTH AMERICA IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%)
      • FIGURE 106     NORTH AMERICA IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 107     NORTH AMERICA CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 108     NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 109     NORTH AMERICA IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 110     NORTH AMERICA ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%)
      • FIGURE 111     NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE, BY CANCER CARE, (2021 V/S 2028) (%)
      • FIGURE 112     NORTH AMERICA INFECTIOUS DISEASES MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 113     NORTH AMERICA BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 114     NORTH AMERICA VIRAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 115     NORTH AMERICA FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 116     NORTH AMERICA OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 117     NORTH AMERICA IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
      • FIGURE 118     NORTH AMERICA IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
      • FIGURE 119     NORTH AMERICA IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%)
      • FIGURE 120     U.S. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 121     U.S. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 122     U.S. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 123     REST OF N.A. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 124     REST OF N.A. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 125     REST OF N.A. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 126     EUROPE IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
      • FIGURE 127     EUROPE IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%)
      • FIGURE 128     EUROPE IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 129     EUROPE CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 130     EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 131     EUROPE IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 132     EUROPE ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%)
      • FIGURE 133     EUROPE ONCOLOGY MARKET SHARE, BY CANCER CARE, (2021 V/S 2028) (%)
      • FIGURE 134     EUROPE INFECTIOUS DISEASES MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 135     EUROPE BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 136     EUROPE VIRAL INFECTION MARKET SHARE, BY INFECTION, (2021 V/S 2028) (%)
      • FIGURE 137     EUROPE FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 138     EUROPE OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 139     EUROPE IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
      • FIGURE 140     EUROPE IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
      • FIGURE 141     EUROPE IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%)
      • FIGURE 142     GERMANY IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 143     GERMANY IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 144     GERMANY IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 145     U.K. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 146     U.K. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 147     U.K. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 148     FRANCE IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 149     FRANCE IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 150     FRANCE IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 151     REST OF E.U. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 152     REST OF E.U. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 153     REST OF E.U. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 154     APAC IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
      • FIGURE 155     APAC IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%)
      • FIGURE 156     APAC IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 157     APAC CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 158     APAC MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 159     APAC IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 160     APAC ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%)
      • FIGURE 161     APAC ONCOLOGY MARKET SHARE, BY CANCER CARE, (2021 V/S 2028) (%)
      • FIGURE 162     APAC INFECTIOUS DISEASES MARKET SHARE BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 163     APAC BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 164     APAC VIRAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 165     APAC FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 166     APAC OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 167     APAC IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
      • FIGURE 168     APAC IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
      • FIGURE 169     APAC IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%)
      • FIGURE 170     JAPAN IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 171     JAPAN IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 172     JAPAN IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 173     CHINA IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 174     CHINA IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 175     CHINA IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 176     INDIA IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 177     INDIA IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 178     INDIA IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 179     REST OF APAC IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 180     REST OF APAC IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 181     REST OF APAC IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 182     ROW IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%)
      • FIGURE 183     ROW IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%)
      • FIGURE 184     ROW IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 185     ROW CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 186     ROW MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%)
      • FIGURE 187     ROW IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 188     ROW ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%)
      • FIGURE 189     ROW CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE, (2021 V/S 2028) (%)
      • FIGURE 190     ROW INFECTIOUS DISEASES MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%)
      • FIGURE 191     ROW BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 192     ROW VIRAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 193     ROW FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 194     ROW OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%)
      • FIGURE 195     ROW IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%)
      • FIGURE 196     ROW IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%)
      • FIGURE 197     ROW IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%)
      • FIGURE 198     BRAZIL IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 199     BRAZIL IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 200     BRAZIL IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 201     REST OF LATAM IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 202     REST OF LATAM IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 203     REST OF LATIN AMERICA IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 204     MIDDLE EAST & OTHERS IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN)
      • FIGURE 205     MIDDLE EAST & OTHERS MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN)
      • FIGURE 206     MIDDLE EAST & OTHERS IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN)
      • FIGURE 207     KEY GROWTH STRATEGIES (2020-2021)
      • FIGURE 208     SWOT: ABBOTT LABORATORIES
      • FIGURE 209     SWOT: BIOMEREIEUX
      • FIGURE 210     SWOT: DANAHER CORPORATION
      • FIGURE 211     SWOT: DEXCOM INC.
      • FIGURE 212     SWOT: F. HOFFMANN LA ROCHE
      • FIGURE 213     SWOT: HOLOGIC, INC.
      • FIGURE 214     SWOT: QUIDEL CORPORATION
      • FIGURE 215     SWOT: SIEMENS HEALTHINEERS
      • FIGURE 216     SWOT: SYSMEX
      • FIGURE 217     SWOT: THERMO FISHER SCIENTIFIC

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ABACUS DIAGNOSTICA
      • 2     ABBOTT LABORATORIES
      • 3     ABCODIA
      • 4     ABIONIC SA
      • 5     ACCESSDX
      • 6     ACCURAGEN
      • 7     ACCUREX BIOMEDICAL
      • 8     ACRANNOLIFE GENOMICS
      • 9     ADALTIS
      • 10     ADAPTIVE BIOTECHNOLOGIES
      • 11     ADMERA HEALTH
      • 12     ADVANCED CELL DIAGNOSTICS
      • 13     AEGEA BIOTECHNOLOGIES
      • 14     AGAPPE DIAGNOSTICS 
      • 15     AGILENT
      • 16     AKONNI BIOSYSTEMS
      • 17     ALTONA DIAGNOSTICS
      • 18     AMOY DIAGNOSTICS
      • 19     AMS UK
      • 20     ANDINA MEDICA
      • 21     APPLIED DNA SCIENCES, INC.
      • 22     ATLAS MEDICAL
      • 23     AXIS-SHIELD DIAGNOSTICS LTD.
      • 24     AXXIN
      • 25     BABSON DIAGNOSTICS
      • 26     BD
      • 27     BERRY GENOMICS
      • 28     BGI
      • 29     BILLIONTOONE
      • 30     BINX HEALTH
      • 31     BIOAZURE TECHNOLOGIES
      • 32     BIOCARE MEDICAL
      • 33     BIOCAT GMBH
      • 34     BIOCEPT
      • 35     BIOCIENTIFICA SA
      • 36     BIODESIX
      • 37     BIO-GENEX LABORATORIES
      • 38     BIOHELIX
      • 39     BIOMEDICA DIAGNOSTICS INC.
      • 40     BIOMERICA
      • 41     BIOMERIREX
      • 42     BIONEER
      • 43     BIO-RAD
      • 44     BIOTHERANOSTICS
      • 45     BIOVICA INTERNATIONAL AB
      • 46     BRUKER CORPORATION
      • 47     CARDIFF ONCOLOGY
      • 48     CARE DX
      • 49     CAREWELL BIOTECH
      • 50     CENTOGENE
      • 51     CERTEST BIOTEC SL.
      • 52     CHEMBIO DIAGNOSTICS
      • 53     CO-DIAGNOSTICS
      • 54     COLOR HEALTH, INC.
      • 55     COPAN DIAGNOSTICS
      • 56     CREATV MICROTECH INC.
      • 57     CREDO DIAGNOSTICS
      • 58     CTK BIOTECH
      • 59     CURETIS
      • 60     DAAN GENE
      • 61     DAIAGNOSTIC BIOSYSTEMS
      • 62     DANAHER
      • 63     DCN DX
      • 64     DELFI DIAGNOSTICS
      • 65     DEXCOM
      • 66     DIABETOMICS INC. 
      • 67     DIACARTA, INC.
      • 68     DIAGNOSIS
      • 69     DIASORIN
      • 70     DIASOURCE IMMUNOASSAYS S.A.
      • 71     DRUCKER DIAGNOSTICS
      • 72     EKF DIAGNOSTICS
      • 73     ELABSCIENCE
      • 74     ELITECH GROUP
      • 75     ENTERIX, INC
      • 76     ENZO LIFE SCIENCES
      • 77     EPIGENOMICS
      • 78     EPITOPE DIAGNOSTICS
      • 79     EPPENDORF AG
      • 80     ERBA MANNHEIM
      • 81     EUROMEDIX
      • 82     EXACT SCIENCES
      • 83     EXOSOMICS
      • 84     F. HOFFMANN LA ROCHE AG
      • 85     FIRALIS
      • 86     FIRST DIAGNOSTICS CORPORATION
      • 87     FOSUN PHARMA
      • 88     FREENOME
      • 89     FUSION GENOMICS
      • 90     GENEFRON
      • 91     GENEKAM BIOTECHNOLOGY AG
      • 92     GENETIC SIGNATURES
      • 93     GENOMEME
      • 94     GENOMICA
      • 95     GENOPTIX
      • 96     GIRFOLS
      • 97     GLYSENS, INC
      • 98     GODX
      • 99     GRAVITY DIAGNOSTICS, LLC
      • 100     GYROS PROTEIN TECHNOLOGIES
      • 101     HELENA LABORATORIES
      • 102     HOLOGIC(MOBIDIAG)
      • 103     HTG MOLECULAR DIAGNOSTICS
      • 104     HU GROUP(FUJIREBIO DIAGNOSTICS)
      • 105     HUMAN DIAGNOSTICS
      • 106     HUMOR DIAGNOSTICA
      • 107     HYCEL
      • 108     HYCOR BIOMEDICAL
      • 109     IDENTA LTD
      • 110     IGENOMIX
      • 111     ILEX SOUTH AFRICA 
      • 112     ILLUMINA
      • 113     IMMUCOR INC.
      • 114     IMMUDEX
      • 115     IMMUNO SCIENCE (I) PVT. LTD
      • 116     IMMUNODIAGNOSTIC SYSTEMS
      • 117     INBIOS
      • 118     INCELLDX
      • 119     INDEC DIAGNOSTICS
      • 120     INFINITY BIOLOGIX LLC
      • 121     INFLAMMATIX, INC
      • 122     INOCHEM
      • 123     INSILIXA,
      • 124     INTERLABSERVICE LTD.
      • 125     INVIVOSCRIBE, INC.
      • 126     J MITRO & CO. PVT. LTD.
      • 127     JANT PHARMACAL CORPORATION.
      • 128     KAMINENI LIFE SCIENCE
      • 129     KARIUS, INC.
      • 130     KEPHERA DIAGNOSTICS
      • 131     LABORATORIOS LICON S.A.
      • 132     LABORATORIOS RUBIO
      • 133     LIFESCAN
      • 134     LIGHTDECK DIAGNOSTICS
      • 135     LINEAR CHEMICALS S.L.U.
      • 136     LUCIGEN
      • 137     LUMINEX
      • 138     LUMINOUS BIOSCIENCES,
      • 139     LUMOS DIAGNOSTICS
      • 140     MAMMOTH BIOSCIENCES
      • 141     MAPMYGENOME INDIA LTD
      • 142     MAST GROUP
      • 143     MATMACORP
      • 144     MEDICA CORPORATION
      • 145     MEDMIRA
      • 146     MEDTRONIC
      • 147     MENARINI SILICON BIOSYSTEMS
      • 148     MERIDIAN BIOSCIENCE INC.
      • 149     METAMARK GENETICS, INC.
      • 150     MICROPOINT BIOSCIENCE
      • 151     MINDRAY
      • 152     MIP DIAGNOSTICS
      • 153     MIRDETECT
      • 154     MOLBIO DIAGNOSTICS PVT. LTD.
      • 155     MONOBIND INC.
      • 156     MP BIOMEDICALS
      • 157     MRK DIAGNOSTICS
      • 158     MYBIOSOURCE
      • 159     MYLAB
      • 160     MYRIAD GENETICS
      • 161     NANOREPRO
      • 162     NANOSPEED DIAGNOSTICS
      • 163     NANOSTRING TECHNOLOGIES
      • 164     NATERA
      • 165     NEOGENOMICS LABORATORIES, INC
      • 166     NERMADIC
      • 167     NG BIOTECH
      • 168     NGAIO DIAGNOSTICS
      • 169     NOVA BIOMEDICAL
      • 170     NOVISCEND
      • 171     NOVODIAX INC
      • 172     NOW DIAGNOSTIX
      • 173     NRICHDX
      • 174     NUCLEIX
      • 175     NUVIEW LIFE SCIENCES
      • 176     OMEGA DIAGNOSTICS
      • 177     ONCGNOSTICS
      • 178     ONCIMMUNE
      • 179     ONTERA INC.
      • 180     OPKO HEALTH, INC
      • 181     OPTIGENE
      • 182     ORASURE TECHNOLOGIES
      • 183     ORGENTEC DIAGNOSTICS 
      • 184     ORTHO CLINICAL DIAGNOSTICS
      • 185     OXFORD GENE TECHNOLOGY
      • 186     PACIFIC BIOSCIENCES
      • 187     PACIFIC EDGE LIMITED
      • 188     PANAGENE
      • 189     PERKINELMER (OXFORD IMMUNOTEC)
      • 190     PEROSPHERE TECHNOLOGIES INC
      • 191     PERSONAL GENOME DIAGNOSTICS INC
      • 192     PERSONALIZED GENOMICS (PGL) 
      • 193     PHC HOLDING (ASCENCIA DIABETES)
      • 194     PHOENIX MEDICARE
      • 195     PICTOR LIMITED
      • 196     PLEXBIO CO., LTD.
      • 197     POLYMER TECHNOLOGY SYSTEMS
      • 198     POSITIVE BIOSCIENCE
      • 199     PRECIPIO
      • 200     PRECISION BIOLOGIC
      • 201     PREDICINE, INC.
      • 202     PREMIER MEDICAL CORPORATION PVT. LTD.
      • 203     PRESTIGE DIAGNOSTICS
      • 204     PROCISEDX
      • 205     PROMEGA CORPORATION
      • 206     PRONTO DIAGNOSTICS 
      • 207     QIAGEN
      • 208     QUANTUMDX
      • 209     QUIDEL
      • 210     R&D SYSTEMS
      • 211     RANDOX LABORATORIES
      • 212     RESPOSE BIOMEDICAL
      • 213     RHYTHM BIOSCIENCES
      • 214     SAVYON DIAGNOSTICS
      • 215     SCOPE FLUIDICS 
      • 216     SEASUN BIOMATERIALS
      • 217     SEEGENE
      • 218     SEKISUI DIAGNOSTICS
      • 219     SENSONICS
      • 220     SENTINEL DIAGNOSTICS
      • 221     SERACARE LIFE SCIENCES INC.
      • 222     SHERLOCK BIOSCIENCES
      • 223     SIDX
      • 224     SIEMENS HEALTHINEERS
      • 225     SIMPLE DIAGNOSTICS
      • 226     SOLGENT
      • 227     SOMAGEN DIAGNOSTICS INC
      • 228     SPEEDX
      • 229     STAGEZERO LIFE SCIENCES
      • 230     SURMODICS
      • 231     SYNAPSE DIAGNOSTICS PVT LTD
      • 232     SYSMEX
      • 233     TAKARA BIO, INC
      • 234     TECO DIAGNOSTICS
      • 235     TEL-ARRAY
      • 236     THERADIAG
      • 237     THERMOFISHER
      • 238     TODOS MEDICAL
      • 239     TRANSASIA BIO-MEDICALS LTD.
      • 240     TRINITY BIOTECH
      • 241     TRUE DIAGNOSTICS
      • 242     TRUVIAN SCIENCES
      • 243     TULIP DIAGNOSTICS
      • 244     TWINSTRAND BIOSCIENCES
      • 245     TWIST DIAGNOSTICS
      • 246     USTAR BIOTECHNOLOGIES
      • 247     VELA DIAGNOSTICS
      • 248     VICTORIAN CLINICAL GENETICS SERVICES
      • 249     VISBY MEDICAL
      • 250     WAMA DIAGNÓSTICA
      • 251     WERFEN
      • 252     WUXI DIAGNOSTICS
      • 253     XEMA-MEDICA CO. LTD
      • 254     YOURGENE BIOSCIENCES
      • 255     ZEUS SCIENTIFIC INC.
      • 256     ZHUHAI DL BIOTECH. CO., LTD.